Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 463 entries
Sorted by: Best Match Show Resources per page
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation …

evaluation

[No authors listed]
GSID: eayDFtIPXEQJ
LH Lindholm, M Persson, P Alaupovic… - Journal of …, 2003 - journals.lww.com

Objective The aim of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation study was to compare the long-term effect of the commonly used inexpensive medication with a low-dose diuretic (hydrochlorothiazide), alone or in combination...

Cite
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B. O., Svensson, A., & Samuelsson, O. (2003). Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). Journal of hypertension, 21(8), 1563-1574.
Lindholm, Lars H., et al. "Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)." Journal of hypertension 21.8 (2003): 1563-1574.
Copy Download .nbib Format: MLA
The Last Nail in Hydrochlorothiazide's Coffin?.

The Ochsner journal

Al Badarin FJ, Lavie CJ, O'Keefe JH.
PMID: 22438773
Ochsner J. 2012;12(1):4-6.

No abstract available.

Cite
Al Badarin FJ, Lavie CJ, O'Keefe JH. The Last Nail in Hydrochlorothiazide's Coffin?. Ochsner J. 2012;12(1):4-6
Al Badarin, F. J., Lavie, C. J., & O'Keefe, J. H. (2012). The Last Nail in Hydrochlorothiazide's Coffin?. The Ochsner journal, 12(1), 4-6.
Al Badarin, Firas J, et al. "The Last Nail in Hydrochlorothiazide's Coffin?." The Ochsner journal vol. 12,1 (2012): 4-6.
Al Badarin FJ, Lavie CJ, O'Keefe JH. The Last Nail in Hydrochlorothiazide's Coffin?. Ochsner J. 2012;12(1):4-6. PMID: 22438773; PMCID: PMC3307504.
Copy Download .nbib Format: NLM
Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial.

American journal of cardiovascular drugs : drugs, devices, and other interventions

Sohn IS, Kim CJ, Oh BH, Hong TJ, Park CG, Kim BS, Chung WB.
PMID: 26994003
Am J Cardiovasc Drugs. 2016 Apr;16(2):139. doi: 10.1007/s40256-016-0167-2.

No abstract available.

Cite
Sohn IS, Kim CJ, Oh BH, et al. Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. Am J Cardiovasc Drugs. 2016;16(2):139doi: 10.1007/s40256-016-0167-2.
Sohn, I. S., Kim, C. J., Oh, B. H., Hong, T. J., Park, C. G., Kim, B. S., Chung, W. B. (2016). Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions, 16(2), 139. https://doi.org/10.1007/s40256-016-0167-2
Sohn, Il Suk, et al. "Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial." American journal of cardiovascular drugs : drugs, devices, and other interventions vol. 16,2 (2016): 139. doi: https://doi.org/10.1007/s40256-016-0167-2
Sohn IS, Kim CJ, Oh BH, Hong TJ, Park CG, Kim BS, Chung WB. Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. Am J Cardiovasc Drugs. 2016 Apr;16(2):139. doi: 10.1007/s40256-016-0167-2. PMID: 26994003; PMCID: PMC4969791.
Copy Download .nbib Format: NLM
A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg.

Blood pressure

T McINNES G, Istad H, Keinänen-Kiukaanniemi S, VAN Mierlo HFCM.
PMID: 28425809
Blood Press. 2000;9:61. doi: 10.1080/080370500439344.

Monotherapy with an antihypertensive agent is likely to achieve a desirable lowering of blood pressure in about 50% of patients. The remaining proportion of patients are likely to be only partially responsive or unresponsive, even if appropriate dose adjustments...

Cite
T McINNES G, Istad H, Keinänen-Kiukaanniemi S, et al. A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg. Blood Press. 2000;9:61doi: 10.1080/080370500439344.
T McINNES, G., Istad, H., Keinänen-Kiukaanniemi, S., & VAN Mierlo, H. F. C. M. (2000). A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg. Blood pressure, 961. https://doi.org/10.1080/080370500439344
T McINNES, G, et al. "A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg." Blood pressure vol. 9 (2000): 61. doi: https://doi.org/10.1080/080370500439344
T McINNES G, Istad H, Keinänen-Kiukaanniemi S, VAN Mierlo HFCM. A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg. Blood Press. 2000;9:61. doi: 10.1080/080370500439344. PMID: 28425809.
Copy Download .nbib Format: NLM
In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients.

Therapeutics and clinical risk management

Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH.
PMID: 27703364
Ther Clin Risk Manag. 2016 Sep 19;12:1425-1432. doi: 10.2147/TCRM.S110727. eCollection 2016.

OBJECTIVES: The objectives of this study were to evaluate the general quality of the most prescribed products of valsartan (VL; alone or in combination) and to evaluate their efficacy and safety among Palestinian population through in vivo postmarketing surveillance.PATIENTS...

Cite
Zaid AN, Ghanem M, Shweiki D, et al. In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Ther Clin Risk Manag. 2016;12:1425-1432doi: 10.2147/TCRM.S110727.
Zaid, A. N., Ghanem, M., Shweiki, D., Shtewi, H., Shaheen, R., Al Helaly, S., Khayyat, Z., Al Ramahi, R., & Zyoud, S. H. (2016). In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Therapeutics and clinical risk management, 121425-1432. https://doi.org/10.2147/TCRM.S110727
Zaid, Abdel Naser, et al. "In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients." Therapeutics and clinical risk management vol. 12 (2016): 1425-1432. doi: https://doi.org/10.2147/TCRM.S110727
Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH. In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Ther Clin Risk Manag. 2016 Sep 19;12:1425-1432. doi: 10.2147/TCRM.S110727. eCollection 2016. PMID: 27703364; PMCID: PMC5036554.
Copy Download .nbib Format: NLM
Scrotal Swelling as a Complication of Hydrochlorothiazide Induced Acute Pancreatitis.

Case reports in gastrointestinal medicine

Nikiforov I, Mansoora Q, Al-Khalisy H, Joseph S, Cheriyath P.
PMID: 26199765
Case Rep Gastrointest Med. 2015;2015:265273. doi: 10.1155/2015/265273. Epub 2015 Jun 24.

Background. Scrotal swelling is a rare complication of acute pancreatitis with few reported cases in the literature. In this case report, we present a 59-year-old male with hydrochlorothiazide induced pancreatitis who developed scrotal swelling. Case Presentation. A 59-year-old male...

Cite
Nikiforov I, Mansoora Q, Al-Khalisy H, et al. Scrotal Swelling as a Complication of Hydrochlorothiazide Induced Acute Pancreatitis. Case Rep Gastrointest Med. 2015;2015:265273doi: 10.1155/2015/265273.
Nikiforov, I., Mansoora, Q., Al-Khalisy, H., Joseph, S., & Cheriyath, P. (2015). Scrotal Swelling as a Complication of Hydrochlorothiazide Induced Acute Pancreatitis. Case reports in gastrointestinal medicine, 2015265273. https://doi.org/10.1155/2015/265273
Nikiforov, Ivan, et al. "Scrotal Swelling as a Complication of Hydrochlorothiazide Induced Acute Pancreatitis." Case reports in gastrointestinal medicine vol. 2015 (2015): 265273. doi: https://doi.org/10.1155/2015/265273
Nikiforov I, Mansoora Q, Al-Khalisy H, Joseph S, Cheriyath P. Scrotal Swelling as a Complication of Hydrochlorothiazide Induced Acute Pancreatitis. Case Rep Gastrointest Med. 2015;2015:265273. doi: 10.1155/2015/265273. Epub 2015 Jun 24. PMID: 26199765; PMCID: PMC4495177.
Copy Download .nbib Format: NLM
Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations.

World journal of methodology

Al Shibli A, Narchi H.
PMID: 26140272
World J Methodol. 2015 Jun 26;5(2):55-61. doi: 10.5662/wjm.v5.i2.55. eCollection 2015 Jun 26.

Bartter and Gitelman syndromes (BS and GS) are inherited disorders resulting in defects in renal tubular handling of sodium, potassium and chloride. Previously considered as genotypic and phenotypic heterogeneous diseases, recent evidence suggests that they constitute a spectrum of...

Cite
Al Shibli A, Narchi H. Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. World J Methodol. 2015;5(2):55-61doi: 10.5662/wjm.v5.i2.55.
Al Shibli, A., & Narchi, H. (2015). Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. World journal of methodology, 5(2), 55-61. https://doi.org/10.5662/wjm.v5.i2.55
Al Shibli, Amar, and Narchi, Hassib. "Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations." World journal of methodology vol. 5,2 (2015): 55-61. doi: https://doi.org/10.5662/wjm.v5.i2.55
Al Shibli A, Narchi H. Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. World J Methodol. 2015 Jun 26;5(2):55-61. doi: 10.5662/wjm.v5.i2.55. eCollection 2015 Jun 26. PMID: 26140272; PMCID: PMC4482822.
Copy Download .nbib Format: NLM
Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital.

Avicenna journal of medicine

Sivva D, Mateti UV, Neerati VM, Thiruthopu NS, Martha S.
PMID: 25878964
Avicenna J Med. 2015 Apr-Jun;5(2):29-35. doi: 10.4103/2231-0770.154194.

OBJECTIVE: The objective of the study was to assess the incidence and pattern of drug-drug interactions (DDIs) in hypertensive patients by using Micromedex and Medscape databases.MATERIALS AND METHODS: A prospective observational study was carried out in a superspeciality hospital...

Cite
Sivva D, Mateti UV, Neerati VM, et al. Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital. Avicenna J Med. 2015;5(2):29-35doi: 10.4103/2231-0770.154194.
Sivva, D., Mateti, U. V., Neerati, V. M., Thiruthopu, N. S., & Martha, S. (2015). Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital. Avicenna journal of medicine, 5(2), 29-35. https://doi.org/10.4103/2231-0770.154194
Sivva, Divya, et al. "Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital." Avicenna journal of medicine vol. 5,2 (2015): 29-35. doi: https://doi.org/10.4103/2231-0770.154194
Sivva D, Mateti UV, Neerati VM, Thiruthopu NS, Martha S. Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital. Avicenna J Med. 2015 Apr-Jun;5(2):29-35. doi: 10.4103/2231-0770.154194. PMID: 25878964; PMCID: PMC4394569.
Copy Download .nbib Format: NLM
A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals.

Annals of translational medicine

Summers EM, Blickenstaff NR, Coman GC, Martins TB, Hill HR, Sontheimer RD.
PMID: 29152493
Ann Transl Med. 2017 Oct;5(20):393. doi: 10.21037/atm.2017.07.16.

BACKGROUND: Identifying the drug(s) responsible for drug-induced chronic eczematous eruptions of aging individuals (CEEA) is a clinical challenge in patients on multiple medications. Reliable METHODS: This was a single center, proof-of-concept pilot study at the University of Utah Hospital,...

Cite
Summers EM, Blickenstaff NR, Coman GC, et al. A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals. Ann Transl Med. 2017;5(20):393doi: 10.21037/atm.2017.07.16.
Summers, E. M., Blickenstaff, N. R., Coman, G. C., Martins, T. B., Hill, H. R., & Sontheimer, R. D. (2017). A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals. Annals of translational medicine, 5(20), 393. https://doi.org/10.21037/atm.2017.07.16
Summers, Erika Mae, et al. "A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals." Annals of translational medicine vol. 5,20 (2017): 393. doi: https://doi.org/10.21037/atm.2017.07.16
Summers EM, Blickenstaff NR, Coman GC, Martins TB, Hill HR, Sontheimer RD. A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals. Ann Transl Med. 2017 Oct;5(20):393. doi: 10.21037/atm.2017.07.16. PMID: 29152493; PMCID: PMC5673781.
Copy Download .nbib Format: NLM
Baseline Serum Aldosterone-to-Renin Ratio is Associated with the Add-on Effect of Thiazide Diuretics in Non-Diabetic Essential Hypertensives.

Acta Cardiologica Sinica

Huang CC, Leu HB, Huang PH, Wu TC, Lin SJ, Chen JW.
PMID: 27122683
Acta Cardiol Sin. 2013 Jan;29(1):37-48.

BACKGROUND: The baseline status of renin-angiotensin-aldosterone system (RAAS) might modify the blood pressure (BP) lowering effects of thiazide diuretics. This study aimed to determine if baseline RAAS indicated by serum aldosterone-to-renin ratio (ARR) could be associated with the add-on...

Cite
Huang CC, Leu HB, Huang PH, et al. Baseline Serum Aldosterone-to-Renin Ratio is Associated with the Add-on Effect of Thiazide Diuretics in Non-Diabetic Essential Hypertensives. Acta Cardiol Sin. 2013;29(1):37-48
Huang, C. C., Leu, H. B., Huang, P. H., Wu, T. C., Lin, S. J., & Chen, J. W. (2013). Baseline Serum Aldosterone-to-Renin Ratio is Associated with the Add-on Effect of Thiazide Diuretics in Non-Diabetic Essential Hypertensives. Acta Cardiologica Sinica, 29(1), 37-48.
Huang, Chin-Chou, et al. "Baseline Serum Aldosterone-to-Renin Ratio is Associated with the Add-on Effect of Thiazide Diuretics in Non-Diabetic Essential Hypertensives." Acta Cardiologica Sinica vol. 29,1 (2013): 37-48.
Huang CC, Leu HB, Huang PH, Wu TC, Lin SJ, Chen JW. Baseline Serum Aldosterone-to-Renin Ratio is Associated with the Add-on Effect of Thiazide Diuretics in Non-Diabetic Essential Hypertensives. Acta Cardiol Sin. 2013 Jan;29(1):37-48. PMID: 27122683; PMCID: PMC4804959.
Copy Download .nbib Format: NLM
Conceptuation, formulation and evaluation of sustained release floating tablets of captopril compression coated with gastric dispersible hydrochlorothiazide using 2(3) factorial design.

International journal of pharmaceutical investigation

Sirisha PL, Babu GK, Babu PS.
PMID: 25006552
Int J Pharm Investig. 2014 Apr;4(2):77-87. doi: 10.4103/2230-973X.133055.

Ambulatory blood pressure monitoring is regarded as the gold standard for hypertensive therapy in non-dipping hypertension patients. A novel compression coated formulation of captopril and hydrochlorothiazide (HCTZ) was developed in order to improve the efficacy of antihypertensive therapy considering...

Cite
Sirisha PL, Babu GK, Babu PS. Conceptuation, formulation and evaluation of sustained release floating tablets of captopril compression coated with gastric dispersible hydrochlorothiazide using 2(3) factorial design. Int J Pharm Investig. 2014;4(2):77-87doi: 10.4103/2230-973X.133055.
Sirisha, P. L., Babu, G. K., & Babu, P. S. (2014). Conceptuation, formulation and evaluation of sustained release floating tablets of captopril compression coated with gastric dispersible hydrochlorothiazide using 2(3) factorial design. International journal of pharmaceutical investigation, 4(2), 77-87. https://doi.org/10.4103/2230-973X.133055
Sirisha, Pathuri Lakshmi, et al. "Conceptuation, formulation and evaluation of sustained release floating tablets of captopril compression coated with gastric dispersible hydrochlorothiazide using 2(3) factorial design." International journal of pharmaceutical investigation vol. 4,2 (2014): 77-87. doi: https://doi.org/10.4103/2230-973X.133055
Sirisha PL, Babu GK, Babu PS. Conceptuation, formulation and evaluation of sustained release floating tablets of captopril compression coated with gastric dispersible hydrochlorothiazide using 2(3) factorial design. Int J Pharm Investig. 2014 Apr;4(2):77-87. doi: 10.4103/2230-973X.133055. PMID: 25006552; PMCID: PMC4083537.
Copy Download .nbib Format: NLM
Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies.

BMJ global health

Tonelli M, Wiebe N, Nadler B, Darzi A, Rasheed S.
PMID: 28588970
BMJ Glob Health. 2016 Oct 20;1(3):e000128. doi: 10.1136/bmjgh-2016-000128. eCollection 2016.

The Interagency Emergency Health Kit (IEHK) provides a standard package of medicines and simple medical devices for aid agencies to use in emergencies such as disasters and armed conflicts. Despite the increasing burden of non-communicable diseases (NCDs) in such...

Cite
Tonelli M, Wiebe N, Nadler B, et al. Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ Glob Health. 2016;1(3):e000128doi: 10.1136/bmjgh-2016-000128.
Tonelli, M., Wiebe, N., Nadler, B., Darzi, A., & Rasheed, S. (2016). Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ global health, 1(3), e000128. https://doi.org/10.1136/bmjgh-2016-000128
Tonelli, Marcello, et al. "Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies." BMJ global health vol. 1,3 (2016): e000128. doi: https://doi.org/10.1136/bmjgh-2016-000128
Tonelli M, Wiebe N, Nadler B, Darzi A, Rasheed S. Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ Glob Health. 2016 Oct 20;1(3):e000128. doi: 10.1136/bmjgh-2016-000128. eCollection 2016. PMID: 28588970; PMCID: PMC5321368.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 463 entries